Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

Australian pharmaceutical companies retreated in morning trade after shares in US pharma giant Eli Lilly dived 14% overnight, due disappointing data on its new oral weight loss pill.

A late-stage study tested three doses of Eli Lilly’s oral GLP-1 drug, Orforglipron, in more than 3,100 adults, with the ...